Sign up for alerts
Want to make sure you never miss the latest updates?
Insights with impact
Industry Insight
The biology of roginolisib: Activity without immune toxicity
Industry Insight
End of year reflections from our CEO
Industry Insight
Driving breakthroughs for myelofibrosis care
Industry Insight
What’s next for cambritaxestat?
Industry Insight
Realizing the potential of PI3Kδ inhibitors in peripheral T-cell lymphomas
Industry Insight
iOnctura expands roginolisib trials to the US
Industry Insight
iOnctura enhances board to accelerate growth and innovation
Industry Insight
Addressing drug resistance in non-small cell lung cancer
Industry Insight
Scientific innovation in uveal melanoma
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
Download our corporate deck
Find out more about our mission to give patients more momets that matter
All news
Data & publication
The PI3Kδ inhibitor roginolisib (IOA-244) preserves T-cell function and activity
Data & publication
The selective PI3Kδ inhibitor roginolisib synergizes with ruxolitinib against progenitor cells from naïve and JAKi-refractory/resistant patients with myelofibrosis
Data & publication
Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL)
Data & publication
PlaΤform: A multicenter, multi-arm, academic platform trial evaluating novel agents and combinations in relapsed or refractory peripheral T-cell lymphomas
Data & publication
Trial in progress: A study of roginolisib in combination with ruxolitinib in patients with myelofibrosis who are unresponsive to JAK inhibitors (HEMA-MED)
Data & publication
Safety and clinical efficacy of cambritaxestat (IOA-289), a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
Data & publication
The PI3Kδ inhibitor roginolisib (IOA-244) preserves T cell function and activity
Data & publication
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies
Data & publication
A Randomised Phase II Study of Roginolisib in Patients With Advanced / Metastatic Ocular / Uveal Melanoma (OCULE-01)
Data & publication
Molecular profiling of the PI3Kδ inhibitor roginolisib in metastatic uveal melanoma and its correlation with clinical outcomes
Data & publication
Transforming growth factor beta receptor type I (TGF-βRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS
Data & publication
High levels of autotaxin and lysophosphatidic acid predict poor outcome in treatment of resectable gastric carcinoma
Looking for media
resources?